April 2023

Schizophrenic Brain Glutamate Levels Compared With General Population
Previous research has established that glutamatergic dysfunction plays a role in the pathogenesis of schizophrenia; however, it is uncertain if the extent of glutamatergic dysfunction is comparable among individuals with schizophrenia or if there are significant variances among this patient population when compared with the general population. A new study published in Molecular Psychiatry explores these variances. Read more.


Exploring Combined Treatment for Motivational Negative Symptoms
In a recent publication in The American Journal of Psychiatry, researchers conducted a randomized, controlled study to evaluate the role of an innovative psychosocial intervention that employed two evidence-based practices—motivational interviewing and cognitive-behavioral therapy—for the treatment of motivational negative symptoms often associated with schizophrenia. Learn more about the results of this study.

Two Novel Genes That May Heighten Risk for Schizophrenia
Researchers have announced their discovery of two previously unknown genes associated with the incidence of schizophrenia and a third gene carrying the risk for schizophrenia and another developmental disorder. The study revealed that the schizophrenia risk conferred by these variants is conserved across ethnicities. The findings may also lead to the development of novel therapeutics for treating schizophrenia. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App